In May 2024, 29 per cent of the fentanyl samples tested in Philadelphia contained medetomidine. By November it was 87 per cent. In about six months, medetomidine in Philadelphia went from a rare find to the main adulterant in the city’s illicit opioid supply, and hospitals saw the effects straight away.
A veterinary drug in the street supply
Medetomidine is an FDA-approved veterinary sedative. In 2024 it turned up in opioid overdoses in Pennsylvania and Illinois, where patients had a slow heart rate, low blood pressure and unusually long sedation. Earlier, it had shown up in small amounts alongside fentanyl and xylazine in samples from Missouri, Colorado, California and Maryland. The Centers for Disease Control and Prevention has since warned that it is still concentrated in the north-east but spreading.
A withdrawal syndrome clinicians hadn’t seen before
By autumn 2024, frontline staff in Philadelphia’s hospitals reported severe and worsening withdrawal in people using opioids. Emergency department visits for severe opioid withdrawal more than doubled by the end of the year. Doctors in Philadelphia and Pittsburgh described the usual signs of opioid withdrawal plus blood pressure often above 180/120, heart rates above 140, vomiting that wouldn’t stop, an unusual tremor, and in some cases brain swelling and heart muscle injury. In one report, more than 90 per cent of 175 patients went to intensive care.
Standard withdrawal treatment often failed to settle these patients. Clinicians adapted protocols first built for xylazine, but stabilising patients stayed difficult. Many doctors didn’t know what medetomidine withdrawal looked like, and no accessible laboratory test could confirm it.
The Summit
Philadelphia’s health department and the Health Federation of Philadelphia responded by bringing providers together. On 6 November 2025, 115 people attended an in-person Medetomidine Withdrawal Summit. Most worked in medical or behavioural health settings: doctors, nurses, pharmacists, social workers, recovery specialists and outreach workers, plus city staff and researchers. Some travelled from Pittsburgh, New Jersey and New York.
Presenters walked through four real cases, altered to protect identities. In the first, a young man living in supportive housing had his blood pressure checked at repeat visits, and staff had a protocol to send him to hospital if it spiked. In the second, a hospital patient who looked mildly unwell on arrival deteriorated within hours and needed intensive care. In the third, a residential treatment centre with no medical provider required on site around the clock called 911 after a new admission’s blood pressure climbed and his mental state changed. In the fourth, a young woman arrived after an overdose with a slow heart rate and swung to severe hypertension within two hours.
What the experts agreed on
The panel said there is no standard protocol and no validated tool for measuring this type of withdrawal. The common opioid withdrawal scale can understate severity in patients who turn quiet and unresponsive, and those patients most need intervention. Heart rate and blood pressure, panellists said, track severity better than mental status. A past ICU stay for medetomidine withdrawal also predicted future severity better than how much someone reported using.
Naloxone remains the first-line response to opioid overdose, though patients may stay sedated after it, so redosing depends on whether they are breathing adequately. Outside hospital, patients generally need to keep oral medication down, and those who can’t usually need transfer. Pregnancy made treatment particularly challenging, and the panel judged that the benefits of treating withdrawal outweighed the risks of leaving it undertreated.
Twelve recommendations
Attendees offered 74 insights across nine themes, from overdose response to reimbursement. The authors distilled them into twelve recommendations. They call for funded drug checking programmes, inclusion of harm reduction networks in alerts, close monitoring for rapid swings between intoxication and withdrawal, and emergency evaluation for people with profound hypertension. They also want reimbursement that reflects the complexity of care, an ICD code for medetomidine withdrawal, and free accredited training for medical and behavioural health teams.
Limits and what comes next
The paper is a descriptive meeting report, not a trial, and some recommendations rest on anecdotal evidence. The authors acknowledge gaps in outpatient tapering and in coordination with primary care, and they want future work to measure whether the Summit changed clinicians’ confidence. Their conclusion is that hospitals, health organisations and public health agencies need to share observations, data and expertise early when a new substance enters the drug supply.
Source: dbrecoveryresources

Leave a Reply